MONK–(COMMERCIAL LINE) – Box, Inc. (NYSE: Box), the leading Content Cloud, announced today that Polpharma Biologics has chosen Box to power secure content management and collaboration in the cloud. Polpharma Biologics, a European biotechnology company based in Poland and the Netherlands, uses Box as a single and integrated solution to centralize sensitive and regulated content in the cloud.
“Polpharma Biologics develops biosimilar drugs to increase patient access to much needed therapies. As a biotech company, we know how critical it is to maintain quality in every field and daily activity, “said Bartlomiej Piernicki, Business Technology Director of Polpharma Biologics.” With Box, we are standardizing all regulated and unregulated content into a single validated platform and secure. This ensures that our teams can access content easily and securely and collaborate with partners throughout the drug manufacturing process, from early stage discovery to development. ”
“Polpharma Biologics is one of the most modern biotech development and manufacturing companies in Europe,” said Michael Mors, Central European General Manager of Box. “We are incredibly excited that Box can play a central role in helping to connect their global teams and partners as they continue their critical work of innovating and developing quality organic products.”
Polpharma Biologics has chosen Box Enterprise Plus for the complete suite of Content Cloud features, including:
Validate Box GxP to seamlessly manage both unregulated and regulated content in the cloud. Polpharma Biologics evaluated the advantages of Box GxP for accelerated validation over incumbent solutions such as Microsoft Sharepoint.
Box Consulting to drive Box adoption and assist in implementation for teams across the company, including R&D, regulatory affairs, and quality assurance.
“The past two years have shown how crucial interinstitutional research and industrial partnerships are to drug development and the manufacturing process,” said Manu Vohra, managing director, Global Life Sciences at Box. “When highly regulated research and IP data are engaged for the next therapeutic breakthrough, organizations are turning to technology platforms to accelerate and harmonize R&D and manufacturing investments, without sacrificing security and compliance.”
Box first announced GxP validation in 2018 as an innovative approach to maintaining GxP compliance in the cloud. With today’s announcement, Polpharma Biologics is joining a growing list of leading life science and biotechnology organizations leveraging Box to empower new ways of working, including AstraZeneca, Amgen and Allergan. For more information on Box for Life Sciences, visit box.com/industries/life-sciences-biotech.
Information about Polpharma Biologics Group
Polpharma Biologics is an international biotechnology company with integrated activities in the EU, which develops and manufactures biosimilar medicines. Using patented solutions and state-of-the-art cell line development platforms, Polpharma Biologics develops biosimilar products for the treatment of a range of conditions in key therapeutic areas. Implement projects from the cell line development phase to industrial scale production, preparing drugs for future business partnerships with global pharmaceutical players. Learn more at www.polpharmabiologics.com.
About the box
Box (NYSE: BOX) is the leading content cloud that enables organizations to accelerate business processes, enhance workplace collaboration, and protect their most valuable information – all while working with a state-of-the-art enterprise IT stack. Founded in 2005, Box makes work easier for leading global organizations, including AstraZeneca, JLL and Morgan Stanley. Box is headquartered in Redwood City, California, with offices in the United States, Europe and Asia. For more information on Box, visit http://www.box.com. To learn more about how Box enables nonprofits to carry out their missions, visit Box.org.